HELIX BIOPHARMA (HBP:TSE) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HELIX BIOPHARMA (HBP:TSE)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Neurogenesis who wrote (32)	5/5/1997 6:18:00 PM
From: Jason Van Bergen	of 193

PharmaDerm's Dermal Drug Delivery Systems offer the potential for significant improvements over existing technologies through a proprietary method of preparation which is well along in the patenting process. These Dermal Drug Delivery Systems allow significant scale-up of the manufacturing process and increased efficiency of drug uptake. Furthermore, these systems do not make use of toxic solvents in preparation like competing systems. As PharmaDerm progresses through clinical trials utilizing the Dermal Drug Delivery Systems, the true worth of the technology will be realized. The first products to which the Dermal Drug Delivery Systems will be applied are generic pharmaceuticals; the clinical trial and approval processes are therefore expected to be rapid for these products. Management at Helix are well aware of other companies that are developing alternative transdermal drug delivery systems. We believe that PharmaDerm's product is a novel approach to transdermal drug delivery, and is superior to other companies' older technologies.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next